Overview

AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Patients without a documented history of AF and will undergo a valve or CABG procedure with direct visual access to the LAA will be eligible to participate. Patients enrolled will be randomized 2:1 (2 with AtriClip to 1 without AtriClip. Subjects who develop POAF and receive the AtriClip will be followed for 365 days post index procedure.
Phase:
Phase 4
Details
Lead Sponsor:
AtriCure, Inc.
Treatments:
Warfarin